MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
56.56
+0.50
+0.89%
After Hours: 56.56 0 0.00% 16:02 10/05 EDT
OPEN
55.56
PREV CLOSE
56.06
HIGH
57.01
LOW
55.43
VOLUME
241.41K
TURNOVER
0
52 WEEK HIGH
82.16
52 WEEK LOW
45.05
MARKET CAP
2.59B
P/E (TTM)
70.77
1D
5D
1M
3M
1Y
5Y
Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Pacira BioSciences (NASDAQ:PCRX) is <a href="https://see...
Seekingalpha · 09/27 13:50
Sevāredent Sourcing Solutions And Pacira BioSciences Collaborate To Provide Expanded Access To EXPAREL For Patients Undergoing Oral And Maxillofacial Procedures
Sevāredent Sourcing Solutions, a Group Purchasing Organization (GPO) that creates a competitive advantage for like-minded dental organizations through best-in-class vendor partnerships that drive supply chain value and
Benzinga · 09/27 12:07
Pacira BioSciences, Sevaredent Partner Over Expanded Access to Exparel for Patients Undergoing Certain Dental Procedures
Pacira BioSciences, Sevaredent Partner Over Expanded Access to Exparel for Patients Undergoing Certain Dental Procedures
MT Newswires · 09/27 11:38
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Zacks · 09/21 22:04
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
Benzinga · 09/21 14:08
Pacira stock falls 15% despite non-opioid pain drug Exparel meeting trial's goals
Pacira BioSciences (NASDAQ:PCRX) <a href="https://seekingalpha...
Seekingalpha · 09/21 13:01
Pacira BioSciences Announces Topline Data From Phase 3 Study Of EXPAREL As Single-Dose Sciatic Nerve Block In Popliteal Fossa For Bunionectomy; Study Achieved Primary, Secondary Endpoints
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours --   -- Company on track
Benzinga · 09/21 12:06
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy
-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours -- -- Company on track to submit supplemental New Drug Application ...
GlobeNewswire · 09/21 12:00
More
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain of the knee; low back and other areas; spasticity and stellate ganglion block of the sympathetic nerves. The company is developing interventions to address debilitating conditions involving the sympathetic nervous system. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular, corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.